Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep:122:785-792.
doi: 10.1016/j.ijid.2022.07.035. Epub 2022 Jul 16.

Cytomegalovirus viremia as a risk factor for mortality in HIV-associated cryptococcal and tuberculous meningitis

Caleb P Skipper  1 , Katherine Huppler Hullsiek  2 , Fiona V Cresswell  3 , Kiiza K Tadeo  4 , Michael Okirwoth  4 , Mark Blackstad  5 , Nelmary Hernandez-Alvarado  5 , Claudia Fernández-Alarcón  5 , Stewart Walukaga  5 , Emily Martyn  6 , Jayne Ellis  6 , Kenneth Ssebambulidde  4 , Lillian Tugume  4 , Edwin Nuwagira  7 , Joshua Rhein  5 , David B Meya  8 , David R Boulware  5 , Mark R Schleiss  5 ; ASTRO-CM and RifT Study Teams
Affiliations

Cytomegalovirus viremia as a risk factor for mortality in HIV-associated cryptococcal and tuberculous meningitis

Caleb P Skipper et al. Int J Infect Dis. 2022 Sep.

Abstract

Objectives: CMV viremia is associated with increased mortality in persons with HIV. We previously demonstrated that CMV viremia was a risk factor for 10-week mortality in antiretroviral therapy (ART)-naïve persons with cryptococcal meningitis. We investigated whether similar observations existed over a broader cohort of patients with HIV-associated meningitis at 18 weeks.

Methods: We prospectively enrolled Ugandans with cryptococcal or TB meningitis into clinical trials in 2015-2019. We quantified CMV DNA concentrations from stored baseline plasma or serum samples from 340 participants. We compared 18-week survival between those with and without CMV viremia.

Results: We included 308 persons with cryptococcal meningitis and 32 with TB meningitis, of whom 121 (36%) had detectable CMV DNA. Baseline CD4+ T-cell counts (14 vs. 24 cells/µl; P = 0.07) and antiretroviral exposure (47% vs. 45%; P = 0.68) did not differ between persons with and without CMV viremia. The 18-week mortality was 50% (61/121) in those with CMV viremia versus 34% (74/219) in those without (P = 0.003). Detectable CMV viremia (adjusted hazard ratio [aHR] 1.60; 95% confidence interval [CI] 1.13-2.25; P = 0.008) and greater viral load (aHR 1.22 per log10 IU/ml increase; 95% CI 1.09-1.35; P <0.001) were positively associated with all-cause mortality through 18 weeks.

Conclusion: CMV viremia at baseline was associated with a higher risk of death at 18 weeks among persons with HIV-associated cryptococcal or TB meningitis, and the risk increased as the CMV viral load increased. Further investigation is warranted to determine whether CMV is a modifiable risk contributing to deaths in HIV-associated meningitis or is a biomarker of immune dysfunction.

Keywords: CMV; Cryptococcal meningitis; Cytomegalovirus; HIV; Tuberculous meningitis.

PubMed Disclaimer

Conflict of interest statement

Declarations of competing interest

The authors have no conflicts of interests to declare.

Figures

Figure 1.
Figure 1.
Kaplan-Meier 18-week survival curves by CMV viremia status. Persons with CMV viremia were more likely to die at 18 weeks than persons without CMV viremia. Seven participants were right-censored before 18 weeks for transfer of care. Figure does not include any multivariate adjustments. P-value calculated by log-rank testing.
Figure 2.
Figure 2.
Death within 18 weeks by CMV viral load group. Figure demonstrating the proportion of participants who died by 18 weeks grouped by level of CMV viral load, in IU/ml. Chi-square P-value = 0.001 when comparing across all groups.
See this image and copyright information in PMC

References

    1. Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7:2106–13. - PubMed
    1. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 2014a;370:2487–98. - PMC - PubMed
    1. Boulware DR, Rolfes MA, Rajasingham R, von Hohenberg M, Qin Z, Taseera K, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis 2014b;20:45–53. - PMC - PubMed
    1. Brantsæter AB, Johannessen A, Holberg-Petersen M, Sandvik L, Naman E, Kivuyo SL, et al. Cytomegalovirus viremia in dried blood spots is associated with an increased risk of death in HIV-infected patients: a cohort study from rural Tanzania. Int J Infect Dis 2012;16:e879–85. - PubMed
    1. Butler EK, Boulware DR, Bohjanen PR, Meya DB. Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda. PLoS One 2012;7:e51291. - PMC - PubMed

MeSH terms